Highly Profitable Texas Pharmacy, Specialty Disease-State Focus

$58.0M

Revenue

$3.3M

SDE

2.7x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

High volume and very profitable pharmacy specializing in specific disease states. This pharmacy has...

Why we like it

The earnings are meaningful in dollar terms: $3.33M EBITDA on $58M revenue at a 2.69x multiple means an unlevered yield north of 35% before debt. If that cash flow holds, the payback period is under three years, which is aggressive for any healthcare asset and gives real downside protection.
Pharmacy is genuinely recession-resistant because patients with chronic disease states do not stop taking maintenance medications when the economy turns. Demand is driven by diagnosis and prescriber relationships, not discretionary spending, so revenue is far more predictable than a retail or consumer business at similar scale.
Specialization in specific disease states creates a real moat through payer contracts, accreditations, and prescriber relationships that take years to build. A generalist retail pharmacy competes on convenience and price; a disease-state specialist competes on clinical capability and network access, which is much harder for a new entrant to replicate.
The volume itself is an operator advantage. At $58M in throughput, this business has scale in purchasing, GPO leverage, and fixed-cost absorption that a smaller pharmacy cannot match, which is precisely what protects the spread between reimbursement and drug cost.

How to improve it

Audit the payer and PBM contract mix in the first 90 days and identify the top reimbursement lines by margin, not by revenue. In specialty pharmacy the profit sits in a handful of therapeutic categories, so understanding concentration and contract renewal timing is the single highest-leverage move a new owner can make.
Push adherence and refill-synchronization programs harder, since retention of existing patients on maintenance therapy is far cheaper than acquiring new scripts. Even a modest improvement in refill capture rate on a $58M book compounds directly into EBITDA with almost no incremental cost.
Expand the prescriber referral network for the existing disease states by adding clinical liaison capacity. The business already has the accreditations and payer access, so the constraint on growth is usually the top of the funnel, meaning new prescriber relationships and covered lives.
Renegotiate drug acquisition costs through GPO consolidation or direct manufacturer relationships now that the buyer controls $58M of purchasing volume. Even a 50 basis point improvement in cost of goods on this revenue base is roughly $290K of pure EBITDA.
Evaluate adding adjacent disease states that share the same payer contracts and clinical infrastructure. Layering a new therapeutic category onto existing accreditations and back-office systems is far more capital-efficient than building a second pharmacy from scratch.
Tighten inventory management on high-cost specialty drugs, where a single unit can carry thousands of dollars in acquisition cost. Reducing days of inventory on hand frees working capital and lowers the risk of shrinkage or expiry write-offs that quietly erode margin.

Diligence notes

The whole deal lives and dies on reimbursement risk, so demand a payer-by-payer breakdown of revenue and gross margin plus every PBM and manufacturer contract with renewal dates. A single adverse reimbursement change or lost accreditation on a concentrated disease state could wipe out a large share of the $3.33M EBITDA overnight.
Scrutinize customer and drug concentration carefully. If a handful of high-cost therapies or a single payer drive most of the profit, the 2.69x multiple is cheap for a reason, and you are underwriting a much riskier cash flow than the headline suggests.
Confirm the EBITDA is real and normalized. Verify it against tax returns and audited financials, adjust for owner compensation and any related-party purchasing, and confirm there are no chargebacks, DIR fees, or clawbacks sitting off the reported number that will hit post-close.
Run a full regulatory and compliance review including DEA, state board of pharmacy standing, accreditation status (URAC, ACHC), and any history of audits or recoupments. Specialty pharmacies are high-scrutiny operations, and an unresolved compliance issue can be an existential problem, not a line-item cost.
Verify the durability of prescriber and referral relationships and how much of the volume is tied to the current owner personally. If scripts follow the seller rather than the institution, the transition risk is severe and a strong post-close support and non-compete package becomes mandatory.
Assess working capital requirements closely, because high-cost specialty inventory and slow payer receivables can tie up substantial cash. Understand the accounts receivable aging and inventory carry needed to run this business day to day so the purchase price is not the only capital you need.

Source

Originally listed on DealStream. View original listing →